Opportunity Information: Apply for RFA HG 14 026
Apply for RFA HG 14 026
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "The Electronic Medical Records and Genomics (eMERGE) Network, Phase III Coordinating Center (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172 Human Genome Research.
- This funding opportunity was created on Jul 17, 2014 and posted on Jul 17, 2014.
- Applicants must submit their applications by Nov 12, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,100,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,100,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education For profit organizations other than small businesses County governments Native American tribal governments (Federally recognized) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Independent school districts Private institutions of higher education Special district governments Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) City or township governments State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The funding opportunity titled "The Electronic Medical Records and Genomics (eMERGE) Network, Phase III Coordinating Center (U01)" (Funding Opportunity Number RFA-HG-14-026) is a National Institutes of Health (NIH) discretionary grant competition issued as a cooperative agreement (U01). Its core goal is to support Phase III of the eMERGE Network by funding a single Coordinating Center responsible for providing centralized infrastructure and operational support that enables the network to continue both genomic discovery and implementation research tied to electronic medical records (EMRs). In practical terms, the announcement is focused less on funding multiple independent research sites and more on ensuring the network has a well-resourced hub that can coordinate activities across participating institutions, standardize approaches, and keep multi-site work moving efficiently and consistently.
This opportunity sits within the health research funding category and is associated with CFDA number 93.172 (Human Genome Research). NIH anticipated making one award under this announcement, with an estimated total funding amount of $1,100,000 and an award ceiling of $1,100,000. The program does not require cost sharing or matching, which means applicants are not expected to commit non-federal funds as a condition of the award. The announcement was posted on July 17, 2014, with the application closing date set for November 12, 2014, and an archive date of December 13, 2014, indicating it is a past opportunity rather than an open, currently accepting competition.
The Coordinating Center supported through this U01 mechanism is intended to serve as the backbone for Phase III eMERGE activities. While the brief description provided does not list specific tasks, the phrase "centralized support and infrastructure" in the context of a large NIH network typically implies responsibilities such as coordinating governance and communications across sites, organizing working groups, supporting collaborative study operations, harmonizing data elements and phenotypes derived from EMRs, facilitating genomic and clinical data integration, supporting data quality control and standard operating procedures, managing timelines and deliverables, and enabling sharing of methods and results across the network. Because eMERGE is explicitly described as combining genomic discovery with implementation research, the Coordinating Center role also commonly includes helping the network move beyond gene discovery into practical use cases in clinical settings, such as supporting workflows for returning genomic results, coordinating evaluation of implementation outcomes, and providing common frameworks for measuring clinical impact across diverse health systems.
Eligibility for this award was broad across U.S.-based organizations, including public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (including small businesses and other than small businesses), and various government entities such as state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The eligibility list also explicitly included a wide range of mission-driven institution types and community-focused entities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and eligible federal agencies. At the same time, the FOA made clear that non-U.S. entities (foreign organizations and foreign institutions) were not eligible to apply, and foreign components as defined by the NIH Grants Policy Statement were not allowed. Likewise, non-domestic components of U.S. organizations were not eligible, reinforcing that the work and the funded coordinating infrastructure were expected to be U.S.-based.
Administratively, NIH provided standard support contacts for technical access issues through the NIH Office of Extramural Research (OER) webmaster (FBOWebmaster@OD.NIH.GOV) and pointed applicants to the full announcement for complete details via the NIH grants guide link. Overall, the opportunity can be summed up as a single, network-level award meant to keep Phase III of eMERGE operating as an integrated national program by funding one central Coordinating Center that supplies the shared infrastructure needed to conduct coordinated genomic discovery and implement genomics in ways that leverage electronic medical record systems.
Frequently Asked Questions (FAQs)
1) What is the title of this funding opportunity?
The funding opportunity is titled "The Electronic Medical Records and Genomics (eMERGE) Network, Phase III Coordinating Center (U01)."
2) What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-HG-14-026.
3) Which federal agency is offering this grant?
This opportunity is offered by the National Institutes of Health (NIH).
4) What type of award mechanism is this?
This is a discretionary grant competition issued as a cooperative agreement (U01).
5) What does it mean that this is a cooperative agreement (U01)?
Based on the information provided, this opportunity uses the U01 cooperative agreement mechanism, which is distinct from a standard research project grant in that it is intended to support a coordinated, network-level effort through a central award.
6) What is the main purpose of this opportunity?
The core goal is to support Phase III of the eMERGE Network by funding a single Coordinating Center that provides centralized infrastructure and operational support so the network can continue genomic discovery and implementation research tied to electronic medical records (EMRs).
7) Is this funding intended for multiple research sites or a single hub?
The opportunity is focused on funding one well-resourced hub (a single Coordinating Center) to coordinate activities across participating institutions, standardize approaches, and keep multi-site work moving efficiently and consistently.
8) How many awards did NIH anticipate making under this announcement?
NIH anticipated making one award.
9) What is the estimated total funding amount for this opportunity?
The estimated total funding amount is $1,100,000.
10) What is the award ceiling?
The award ceiling is $1,100,000.
11) Is cost sharing or matching required?
No. The program does not require cost sharing or matching.
12) What is the associated CFDA number and program area?
The opportunity is associated with CFDA 93.172 (Human Genome Research).
13) When was the opportunity posted?
The announcement was posted on July 17, 2014.
14) What was the application closing date?
The application closing date was November 12, 2014.
15) What is the archive date and what does it imply?
The archive date was December 13, 2014. This indicates the opportunity is a past opportunity rather than an open, currently accepting competition.
16) What is the Coordinating Center expected to do?
The description emphasizes "centralized support and infrastructure" for Phase III eMERGE activities. In the context provided, this typically implies coordinating governance and communications across sites, organizing working groups, supporting collaborative study operations, harmonizing data elements and phenotypes derived from EMRs, facilitating genomic and clinical data integration, supporting data quality control and standard operating procedures, managing timelines and deliverables, and enabling sharing of methods and results across the network.
17) How does implementation research fit into the Coordinating Center role?
Because eMERGE combines genomic discovery with implementation research, the Coordinating Center role commonly includes helping the network move beyond gene discovery into practical clinical use cases, such as supporting workflows for returning genomic results, coordinating evaluation of implementation outcomes, and providing common frameworks for measuring clinical impact across diverse health systems.
18) What kinds of organizations were eligible to apply?
Eligibility was broad across U.S.-based organizations, including public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses and other than small businesses), and government entities such as state, county, and city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
19) Were mission-driven and community-focused institutions included in eligibility?
Yes. The eligibility list explicitly included Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations and eligible federal agencies.
20) Are non-U.S. (foreign) organizations eligible to apply?
No. Non-U.S. entities (foreign organizations and foreign institutions) were not eligible to apply.
21) Are foreign components allowed under this FOA?
No. Foreign components (as defined by the NIH Grants Policy Statement) were not allowed.
22) Are non-domestic components of U.S. organizations eligible?
No. Non-domestic components of U.S. organizations were not eligible, reinforcing that the work and coordinating infrastructure were expected to be U.S.-based.
23) What health research area does this opportunity fall under?
This opportunity sits within the health research funding category and is focused on human genome research in connection with electronic medical records and genomics (eMERGE).
24) Where were applicants directed for technical access issues?
NIH provided a technical access contact through the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
25) Where can someone find complete details for this announcement?
Applicants were pointed to the full announcement via the NIH grants guide link (as referenced in the provided description) for complete details.
26) What is the simplest way to summarize what this award was designed to fund?
It was designed to fund one central Coordinating Center to serve as the backbone for Phase III of the eMERGE Network by supplying shared infrastructure needed to conduct coordinated genomic discovery and implement genomics using electronic medical record systems.
Browse more opportunities from the same category: Health
Next opportunity: The Electronic Medical Records and Genomics (eMERGE) Network, Phase III Central Sequencing and Genotyping Facility (U01)
Previous opportunity: FY2015 NOAA Bay Watershed Education and Training (B WET) Hawaii Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 14 026
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 14 026) also looked into and applied for these:
| Funding Opportunity |
|---|
| The Electronic Medical Records and Genomics (eMERGE) Network, Phase III Central Sequencing and Genotyping Facility (U01) Apply for RFA HG 14 027 Funding Number: RFA HG 14 027 Agency: National Institutes of Health Category: Health Funding Amount: $4,000,000 |
| USAID/Uganda Comprehensive HIV/AIDS and Health Services at the Workplace Activity Apply for RFA 617 14 000007 Funding Number: RFA 617 14 000007 Agency: Uganda USAID Kampala Category: Health Funding Amount: $15,000,000 |
| NINDS CREATE Bio Discovery Track Optimization in Preparation for Development of Biotechnology Products and Biologics (U01) Apply for PAR 14 286 Funding Number: PAR 14 286 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Bio Discovery Track Optimization in Preparation for Development of Biotechnology Products and Biologics (U44) Apply for PAR 14 287 Funding Number: PAR 14 287 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NINDS CREATE Bio Development Track Preclinical and Early phase Clinical Development for Biotechnology Products and Biologics (U44) Apply for PAR 14 289 Funding Number: PAR 14 289 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Comprehensive Community HIV Prevention Program for Key and Vulnerable Populations (CP2) Apply for SOL 621 14 000015 Funding Number: SOL 621 14 000015 Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $73,000,000 |
| NINDS CREATE Bio Development Track Preclinical and Early phase Clinical Development for Biotechnology Products and Biologics (UH2/UH3) Apply for PAR 14 288 Funding Number: PAR 14 288 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Immunobiology of Xenotransplantation (U01) Apply for RFA AI 14 048 Funding Number: RFA AI 14 048 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| AHRQ Health Services Research Demonstration and Dissemination Grants (R18) Apply for PA 14 290 Funding Number: PA 14 290 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| AHRQ Health Services Research Projects (R01) Apply for PA 14 291 Funding Number: PA 14 291 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $250,000 |
| Immunobiology of Xenotransplantation (U19) Apply for RFA AI 14 047 Funding Number: RFA AI 14 047 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Mucosal Environment and HIV Prevention (MEHP II) (R01) Apply for RFA AI 14 036 Funding Number: RFA AI 14 036 Agency: National Institutes of Health Category: Health Funding Amount: $1,200,000 |
| Strengthening Voluntary Medical Male Circumcision (MMC), Early Infant Male Circumcision (EIMC) and Pre Service Education in Lesotho Apply for RFA 674 14 000002 Funding Number: RFA 674 14 000002 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $23,800,000 |
| Enhance global health security and advance International Health Regulations (2005) Apply for EP IDS 14 013 Funding Number: EP IDS 14 013 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $1,000,000 |
| NIH Transformative Research Awards (R01) Apply for RFA RM 14 003 Funding Number: RFA RM 14 003 Agency: National Institutes of Health Category: Health Funding Amount: $15,000,000 |
| Enhance global health security and support International Health Regulations (2005) Apply for EP IDS 14 012 Funding Number: EP IDS 14 012 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $120,000 |
| Bioreactors for Reparative Medicine SBIR Direct Phase II (R44) Apply for RFA HL 15 017 Funding Number: RFA HL 15 017 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Bioreactors for Reparative Medicine (R41/R42) Apply for RFA HL 15 004 Funding Number: RFA HL 15 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Bioreactors for Reparative Medicine (R43/R44) Apply for RFA HL 15 008 Funding Number: RFA HL 15 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Clinical Scientist Development Award in Aging (K08) Apply for RFA AG 15 016 Funding Number: RFA AG 15 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 14 026", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.